Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
May 7 (Reuters) - Danish drug developer Zealand Pharma ZELA.CO reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, and said it would launch a share buyback of up to $200 million. (Reporting by Jesus Calero and Vera Dvorakova) ((jesus.calero@thomsonreuters.com))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)